Inhibition of PI3K/AKT/mTOR signaling in cancer represents a promising therapeutic strategy, with isoform-selective PI3Kα inhibitors showing greater efficiency and less toxicity than pan-PI3K inhibitors (92). Here, MTOR is linked to cancer.